Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.

Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R.

Cells. 2019 Nov 8;8(11). pii: E1409. doi: 10.3390/cells8111409.

2.

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis.

Kuo J, Serrano SS, Grönberg A, Massoumi R, Hansson MJ, Gallay P.

Front Pharmacol. 2019 Sep 26;10:1129. doi: 10.3389/fphar.2019.01129. eCollection 2019.

3.

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR.

J Pharmacol Exp Ther. 2019 Nov;371(2):231-241. doi: 10.1124/jpet.119.261099. Epub 2019 Aug 12.

4.

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.

Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D, Foster R.

PLoS One. 2019 Jun 10;14(6):e0217433. doi: 10.1371/journal.pone.0217433. eCollection 2019.

5.

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, Vuagniaux G, Gallay PA.

PLoS One. 2019 Feb 4;14(2):e0211746. doi: 10.1371/journal.pone.0211746. eCollection 2019.

6.

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Pyles RB, Baum MM, Moss JA.

Open Virol J. 2018 Feb 28;12:1-13. doi: 10.2174/1874357901812010001. eCollection 2018.

7.

Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture.

de Wilde AH, Zevenhoven-Dobbe JC, Beugeling C, Chatterji U, de Jong D, Gallay P, Szuhai K, Posthuma CC, Snijder EJ.

Virology. 2018 Apr;517:148-156. doi: 10.1016/j.virol.2017.11.022. Epub 2017 Dec 15.

8.

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles RB, Marzinke MA, Moss JA, Baum MM.

PLoS One. 2017 Sep 7;12(9):e0184303. doi: 10.1371/journal.pone.0184303. eCollection 2017.

9.

Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replication.

Vidotto A, Morais AT, Ribeiro MR, Pacca CC, Terzian AC, Gil LH, Mohana-Borges R, Gallay P, Nogueira ML.

J Proteome Res. 2017 Apr 7;16(4):1542-1555. doi: 10.1021/acs.jproteome.6b00933. Epub 2017 Mar 27.

PMID:
28317380
10.

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.

Chatterji U, Bobardt M, Schaffer L, Wood M, Gallay PA.

PLoS One. 2016 Jul 21;11(7):e0159511. doi: 10.1371/journal.pone.0159511. eCollection 2016.

11.

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Gallay PA, Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z.

PLoS One. 2016 Apr 22;11(4):e0152036. doi: 10.1371/journal.pone.0152036. eCollection 2016.

12.

C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.

Veazey RS, Chatterji U, Bobardt M, Russell-Lodrigue KE, Li J, Wang X, Gallay PA.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):693-8. doi: 10.1128/AAC.01925-15. Print 2016 Jan.

13.

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R.

PLoS One. 2015 Aug 11;10(8):e0134707. doi: 10.1371/journal.pone.0134707. eCollection 2015.

14.

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA.

Antimicrob Agents Chemother. 2015 May;59(5):2496-507. doi: 10.1128/AAC.04958-14. Epub 2015 Feb 9.

15.

Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.

Hansson MJ, Moss SJ, Bobardt M, Chatterji U, Coates N, Garcia-Rivera JA, Elmér E, Kendrew S, Leyssen P, Neyts J, Nur-E-Alam M, Warneck T, Wilkinson B, Gallay P, Gregory MA.

Chem Biol. 2015 Feb 19;22(2):285-92. doi: 10.1016/j.chembiol.2014.10.023. Epub 2015 Jan 22.

16.

The role of immunophilins in viral infection.

Hopkins S, Gallay PA.

Biochim Biophys Acta. 2015 Oct;1850(10):2103-10. doi: 10.1016/j.bbagen.2014.11.011. Epub 2014 Nov 18.

17.

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.

Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, Naoumov NV.

Gastroenterology. 2015 Feb;148(2):403-14.e7. doi: 10.1053/j.gastro.2014.10.004. Epub 2014 Oct 8.

PMID:
25305505
18.

Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

Lim PJ, Gallay PA.

Curr Opin Virol. 2014 Oct;8:30-7. doi: 10.1016/j.coviro.2014.04.012. Epub 2014 May 27. Review.

19.

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells.

Bobardt M, Chatterji U, Lim P, Gawlik K, Gallay P.

Open Virol J. 2014 Mar 7;8:1-8. doi: 10.2174/1874357901408010001. eCollection 2014.

20.

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV, Gallay PA.

Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. doi: 10.1128/AAC.00016-14. Epub 2014 Mar 31.

Supplemental Content

Loading ...
Support Center